01:59:18 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-18 Bokslutskommuniké 2024
2024-11-19 Kvartalsrapport 2024-Q3
2024-08-20 Kvartalsrapport 2024-Q2
2024-06-07 Ordinarie utdelning CALMA B 0.00 SEK
2024-06-05 Årsstämma 2024
2024-05-21 Kvartalsrapport 2024-Q1
2024-02-20 Bokslutskommuniké 2023
2023-12-14 Extra Bolagsstämma 2023
2023-11-21 Kvartalsrapport 2023-Q3
2023-08-22 Kvartalsrapport 2023-Q2
2023-05-23 Kvartalsrapport 2023-Q1
2023-05-17 Ordinarie utdelning CALMA B 0.00 SEK
2023-05-16 Årsstämma 2023
2023-02-21 Bokslutskommuniké 2022
2022-11-22 Kvartalsrapport 2022-Q3
2022-09-22 Extra Bolagsstämma 2022
2022-08-23 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-05-19 Ordinarie utdelning CALMA B 0.00 SEK
2022-05-17 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2022-02-23 Bokslutskommuniké 2021
2021-10-29 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-19 Ordinarie utdelning CALMA B 0.00 SEK
2021-05-18 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-12-23 Extra Bolagsstämma 2020
2020-11-25 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-20 Kvartalsrapport 2020-Q1
2020-05-15 Ordinarie utdelning CALMA B 0.00 SEK
2020-05-14 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-25 Kvartalsrapport 2019-Q3
2019-11-06 Extra Bolagsstämma 2019
2019-08-27 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning CALMA B 0.00 SEK
2019-05-09 Årsstämma 2019
2019-02-28 Bokslutskommuniké 2018
2018-11-26 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Calmark Sweden är verksamt inom medicinteknik. Bolaget specialiserar sig inom utveckling av diagnostiska verktyg riktade mot nyfödda barn. Tekniken utgår ifrån den egenutvecklade plattformen och används för analys de första veckorna efter födseln. Instrumentet används som biomarkör för att studera blodvärden. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget grundades under 2007 och har sitt huvudkontor i Karlstad.
2023-12-11 12:55:02

Calmark Sweden AB announced today that an exclusive distributor agreement has been signed with the company Techno Orbits in Saudi Arabia regarding Calmark's bilirubin test for newborns.

Techno Orbits was founded in 2007 and is a well-established and successful company with a large market share and extensive experience in the medical technology industry. Company is headquartered in Riyadh and several branches in Saudi Arabia and Amman. The company has approximately 150 employees and has good contacts with the Ministry of Health. Techno Orbits is the market leader in PNA testing and has products for neonatal care, including for the treatment of high bilirubin values.

Approximately half a million children are born annually in Saudi Arabia, and tech products to be sold in the country need to be registered before launch, which Calmark estimates will take 3 - 6 months.

"I am very pleased to have concluded this distributorship agreement as Techno Orbits is cut and dried for our Neo-Bilirubin product. The company has already developed the right customer base, understands the value of being able to test close to patients and knows that our product will make a difference," says Anna Söderlund, CEO of Calmark. "I look forward to a very rewarding collaboration with this motivated distributor!"

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-12-2023 12:55 CET.